Similarly, experimental results from mouse and human lung models indicate that treatment with ursodeoxycholic acid (UDCA), which regulates FXR signaling in mice or human lungs, not only reduces ACE2 expression but also mitigates infection symptoms in mice while lowering infection risk in human lungs [88]. The gene discussed is ACE2; the disease is infection.